Cellectar Biosciences, Inc. Resources

Patients News & Media Investors Contact

Cellectar Biosciences, Inc.

  • Home
  • About
    • Overview
    • Partnerships
    • Management Team
    • Board of Directors
  • Platform
    • Overview
    • Posters & Publications
  • Product Pipeline
    • Overview
    • Iopofosine
  • Clinical Studies
    • Overview
    • Waldenstrom’s Macroglobulinemia Pivotal Study Recruiting
    • Relapsed or Refractory Select B-Cell Malignancies Clinical Study Recruiting
    • Children With Relapsed or Refractory Malignant Cancer Clinical Study Recruiting
  • Patients
  • News & Media
  • Investors
  • Contact

Press Releases

News & Media

News & Media

  • Press Releases
  • Presentations
  • Events

Cellectar Reports Financial Results for First Quarter 2022 and Provides a Corporate Update

May 10, 2022

Cellectar Biosciences Announces Positive DMC Review of Pivotal Trial of Iopofosine in Waldenstrom’s Macroglobulinemia

Apr 26, 2022

Cellectar Biosciences Announces Key Commercial Team Appointments

Apr 12, 2022

Cellectar Reports Financial Results for Year Ended December 2021 and Provides a Corporate Update

Mar 21, 2022

Cellectar to Participate at Upcoming Banking Conferences

Mar 10, 2022

Cellectar Biosciences Announces Executive Leadership Changes

Feb 23, 2022

Cellectar to Participate in Fireside Chat at the H.C. Wainwright Bioconnect Conference

Jan 4, 2022

Cellectar Presented Data from its Ongoing Phase 2 CLOVER-1 Study of Iopofosine I-131 at the 63rd ASH Annual Meeting and Exposition

Dec 13, 2021

Cellectar Biosciences Announces Poster Presentation at the 63rd American Society for Hematology Annual Meeting and Exposition

Dec 8, 2021

Cellectar’s Iopofosine I-131 Exhibits Signals of Efficacy in Phase I Study for Pediatric Brain and Solid Tumors

Nov 16, 2021
    • 1
    • 2
    • 3
    • 4
    • 5
    • 6
    • 7
    • 8
    • 9
    • 10
    • ...30
    © 2023 Cellectar Biosciences, Inc. All Rights Reserved.
    Privacy Policy Disclaimer Sitemap Q&A